Key facts
- It has raised $13.8M; the latest was Early Stage VC in May 2025.
- Notable investors include Dalton Venture, Sanyi Capital (China).
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Xiwei Biomedical Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Xiwei Biomedical Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xiwei Biomedical Technology
Manufacturer of implantable biomedical devices intended to advance regenerative medicine and address global corneal transplantation challenges. The company offers biomimetic corneal implants, advanced polymer-collagen crosslinking technology, and regenerative medical platforms, enabling ophthalmic patients worldwide to access biocompatible, durable, and clinically effective therapeutic options.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Ownership
- Privately Held (backing)
Xiwei Biomedical Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xiwei Biomedical Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xiwei Biomedical Technology in its N-PORT filings yet. We sweep new filings monthly.